HALO - Earnings call transcript Q2 2019 | Halozyme Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, everyone. I would now like to turn the conference over to Al Kildani, Vice President of Investor Relations and Corporate Communications for Halozyme Therapeutics. Mr. Kildani, please begin.

Albert Kildani

Good afternoon, and welcome to our Second Quarter 2019 Financial Results Conference Call.

the press a today will supplementary on call our you the be to of today's find section can slide in addition release after issued close, referenced our In website. Relations Investor presentation that

financial Torley, quarter Chief will Officer, Chief will Financial provide update Officer, Helen will XXXX. and business; our President on and who Leading the our Dr. results Laurie Halozyme's second call an be for Executive the who Seltzer, review our

be making our will statements. I a During listing to we the risks forward-looking refer you SEC full call, for filings and of the uncertainties.

I'll Helen. turn call now over the to

Helen Torley

of everyone and afternoon, the today. update joining us on I'm quarter pleased strong progress Good during XXXX. you provide Halozyme an thank to at for second the

we us Armour, President Alison has drug call, May today's all significant the our who join experience Dr. stages joined welcome overseeing in Research leading over of years clinical portion practice oncology, us also Alison in regulatory with Vice Q&A call. will development submission. as along for Development, of a and in oncologist and and XX the Senior of For

all Let developments. recent summary me of the begin a with key

revenue we million, million a was quarter XX% year-over-year. cash up equivalents And cash, in Firstly, second financial position our securities. finished total in quarter $XXX.X the $XX.X strong with and marketable

formulation for the subcutaneous our highlighted in by strategy the in DARZALEX the U.S. ENHANZE Secondly, submissions continue executing tremendous regulatory by make we Jansen progress to in E.U. recent and of the

or phase first one progress ARGX-XXX. clinic Efgartigimod commencing Argenx and the with a in in Our to of phase make partners continue recently study dosing

detailed is pancreas key of the by announcement December. ENHANZE. and top-line track now more trial And review those evaluating thirdly, X for of pivotal our our progress PEGPHXX on with results I'll recent a With beginning and this provide results metastatic highlights, HALO-XXX cancer Phase

X from ENHANZE potential term Slide business. for of review for our the royalty revenues Turning a the long

leading marketed result our XX X that XX in plus covering rHuPHXX pharmaceutical from over indications, approval and targets development and billion in biotech launches enzyme The sales potential we $X be clinical a We X on revenue multiple net to the assumes drug products in revenues in have licensed products. XXXX. total. royalty royalty average in for to ENHANZE companies XXXX, approximately global This expect in products of on the potential potential in formulated royalty mid-single-digit

Also excludes estimate, the forma goods a expense slide illustrated on operating dotted pro with cost line which the yellow business is of ENHANZE sold.

and royalty expenses only to you drop And business. line are As with revenues. operating incremental project projected the an in the bottom the the similar launch, projected associated note the with would will to revenues estimated next growth revenue we ENHANZE inflection

$XXX will addition, milestone potential of new important And the that contribution of potential I'd not company. continue like now any an In to project payments XXXX, to between million of just collaborations. cumulative source this provide from illustration $XXX reflect add the that we does and end million for to capital

development to dialogue in from companies As companies. with always, partners, potential enhanced large by stage remain ranging active new pharmaceutical technology we

I'll move utilizing currently update provide X enhanced now our the an delivery to and on Slide technologies. marketed drug product

important delivery of patients a revenues HYQVIA, the drug strong our formulation trastuzumab. validation currently on X available are X have technology ENHANZE formulation while These of row, of Halozyme. These are As rituximab, are and markets. top provided in utilizing foundation developed ENHANZE for can marketed products of major that the you there the the to subcutaneous providing globe across note initial launches of the subcutaneous most

in partners' our about pipeline. Looking very excited ahead, product we're the blockbuster development

see exciting of slide, you row pipeline some products. the can middle of the these to Moving

review. X Phase X in is a These by third be include Phase of X undergoing regulatory DARZALEX, We which fixed-dose and Janssen's ENHANZE-based there XXXX end testing of currently that in expect product Roche's testing. Herceptin will the products Perjeta continue or combination to and clinical

provide now a me details few Let more on these products.

of the study. cycle. rate the response Oncology X efficacy which sometimes duration study the these early treatment concentration is data X multiple X Data formulation the last delighted Phase trough its administration minutes, for We're reported of the the for applications intravenous a endpoints hours study oral of was and The DARZALEX held U.S. COLUMBA of Society to Janssen results non-inferior third the month submitted from the The subject and the in regulatory to blockbuster on COLUMBA E.U. of or of X each an lives were of The for patients myeloma. that based in subcutaneous and subcutaneous maximum pharmacogenetics data longer. American its from X X the than overall administration we endpoints. of even June. more IV was that on meeting Day at DARZALEX know compared patients therapy with and from transforming on co-primary XXXX take compared to hours administration. injection many Clinical And presentation X can study COLUMBA median annual

form time availability of Phase the contained trial the that studies. expansion capacity given important for and oncology including development patients, benefit the the even already center form of commercialization. program may and have current into healthcare subcutaneous has community of to infusion An also a potential initiated demonstrate broad the is the The further value DARZALEX, X formulation into COLUMBA will Janssen the of earlier of subcutaneous clinical setting. support constraints. with All Janssen X may the therapy subcutaneous DARZALEX. The the savings lines proposition that potential the allow substantial by and caregivers DARZALEX potential stated of be results offered system. administration benefits

utilizing version launch of growth. Importantly, the still the early be the the subcutaneous in stages IV could formulation of DARZALEX first product drug the where is ENHANZE of

worldwide to in by second XXXX. sales for the analysts billion growth XXXX of $X.X J&J and in DARZALEX globally project of potential quarter For with XXXX, XX% billion $X the sales reported sales currently exceed

to is in studied clinical back fixed-dose product This HERX-positive of and cancer. late-stage early is Roche's breast next combination being the product move Perjeta currently which ENHANZE-based Herceptin. and development, I'll candidate

and As a subsequent the can shorter the X.X doses. for receive patients take X take subsequent dose a a to administration, hours minutes fixed-dose Herceptin combination, X with X reminder, hours up by which for subcutaneous and sequential times and loading substantially With minutes. currently to loading between expected X doses to intravenous X.X dose are and the Perjeta

recent drugs opportunity coming value of that year and XX,XXX second in of a for file to half provides XXXX. in XXXX. the this X for patients to fourth and half look consider to price X fixed-dose the an provide Herceptin combination recently hope the call an it enrollment combined of with most in right the According terms further of program evaluating is by quarter what combined patients the They in Roche, in of Perjeta commented in that the the to regulatory results addressed their submission fixed-dose comparison therapy study completed the this developments may the from immediate Roche convenience. and quarters. on the quarterly IV proposition We E.UX. expect forward this also Roche to indicated combination. form U.S. in approximately combination benefit that and And Phase the market trial is this first in to they

one product to Phase partners' is Phase in into the development regard X we additional programs, end to with clinical lastly, continue to that And Phase currently testing advance of XXXX. our X before expect X

program Phase give Turning X update going I'm next utilizing ENHANZE. row to of bottom on an to the the Slide X

of Phase We Roche. trial, that Squibb, continue to marks the we in to there expect currently were This in and pharmacogenetics to clinical in Phase of the over the from products last X a an dosing our study had We Phase Alexion, Bristol-Myers agreement end fastest X Argenx, patient pleased collaboration in pharmacogenomics five X Phase triggered or partners $X to Halozyme. announce by utilizing of X XXXX, Efgartigimod at This that have safety X a first patient ENHANZE. X the signing payment a million evaluating be just dealt development achievement the first ARGX-XXX products months. with Lilly Argenx time ENHANZE and month by testing. will

this their calls And by Argenx quarterly stated results year-end study that XXXX. from expect they on

During testing product be more pay candidate the a to License forward expected closely to and second the to and filing selected year-end human milestone Collaboration progress under associated target collaboration also a Selection We is with delighted Halozyme. the Argenx The Agreement, not Argenx second our of with by target which could with together. of first for XXXX. our ARGX-XXX. second look payment quarter, commitment work $XX CTA the patient continue factor million a CX, triggered is

planning with plans late-stage drug co-administered has of called completed Phase around technology, portfolio formulation our study Alexion ongoing, ALXNXXXX. is for for their ALXNXXXX subcutaneous a its now its including subcutaneous X strategic CX ALXNXXXX. delivery Alexion next-generation development ENHANZE

In submitted with U.K. prevents initial to which ALXNXXXX binds ENHANZE. XXXX addition, study products and novel of in is albumin-binding the the will the application bi-specific CTA mini-body medicines the study The health start in for of to agency Phase regulatory activation that planned ALXNXXXX late expected is a care C. X Alexion initiation evaluate anti-CX of and and human

evaluating continues of a Phase Bristol And X continuing Squibb an with is for lung stage Lilly development with X X anti-CDXX its X with subcutaneous formulation Phase Eli target. of Myers XbX in non-small Opdivo. a patients. is cancer studies Roche study cell and continuing Phase TECENTRIQ undisclosed

just Phase anticipate remain X this in XXXX, undisclosed we which X In be starts trial X discussed. time. including additional trial, that X ongoing addition X ALXNXXXX, And there'll the starts we Phase to additional at

conviction and expanding that deliver key ENHANZE just XXXX. ENHANZE of horizon, we Perjeta royalty regulatory of that the this exciting has clinic. add Herceptin We mention with first in ENHANZE the has to billion the you further to one active And development review our subcutaneous process. our entered build continues being and the clinical regulatory in to the on potential fixed-dose As followed subsidy in combination forward why could pipeline see heard, the potential in in partners' XXXX. the DARZALEX this process in that partner addition, discussions again you've platform in partners With potential. revenue most $X our by submissions we in I'll have look the new for programs half submissions can remain now to regulatory approximately programs momentum business and And

which around currently Now we result, a constrict Halozyme's to the This our shown temporarily the near oncology tumors development HALO-XXX. is that as tumor therapy. reduce turning to identify high which our The and HA therapy cancer our the oncology intra-tumor in or cancer, for in with pillar represents formerly PEGPHXX results vasculature levels and a with companion of degrades PEGPHXX, and targeted the top-line certain revenue pivotal of exciting of setting tissue hyaluronan potential business X pancreas time very diagnostics, developed study partner centered pillar, announcement is around for patients We're accumulate X. metastatic high Slide second with is pillar increase our of as oncology a Ventana their access tumors. in a HA can diagnostics pressure Roche that Phase

that reminder, conduct approximately events PEGPHXX HALO-XXX overall in with results timing to and study for year, in of a reached of for first-line patients June, have Based survival. ABRAXANE which on upon combination global the XXXX final HALO-XXX with HALO-XXX HA a would of patients high December metastatic months. that evaluating X X.X is overall enrollment As the when announced overall randomized, this of data completed we enrolled survival all number as we HALO-XXX that patients. primary May target survival maturity, in occur at plan the expect endpoint followed with been December maturity, double-blind, least has this analysis top-line Phase XXX single we In by or HALO-XXX pancreas data of gemcitabine year. tumors. XXX cancer We and

And Phase Let's a now their those types. for study an dosing gallbladder The other patients discontinued. the cholangiocarcinoma who pancreas and the for Slide our with another Phase initial was Enrollment cohort XX in assess the have is in turn approximately in of study MORPHEUS update cancer, evaluation enrolling a cancer arm study. in Xb/X following enrollment of with Roche completed. combined to cohort tumor to XbX is and XX patients we're ongoing with total therapy schedule. Halozyme-led second-line Tecentriq X PEGPHXX in And is PEGPHXX still on and patients. PEGPHXX different completed on evaluating

look for initial from forward year. and be to of this expect our is We first cohort before the Without later pillar we oncology the X exciting a results to time able these to data an this end trials HALO-XXX doubt, enhance this year. of trial

results the will discuss in financial With greater that, Laurie? I'll now who Laurie our detail. to turn over call

Laurie Stelzer

afternoon, good everyone. and you, Thank

million of $X.X million quarter partner, year X period. $XX.X a enhanced This for our driven the the a million, million million the XX% by $XX.X Herceptin collecting Collaboration Slide discussion and up $X.X quarter the fees revenue increase by quarter the and from financial Argenx. primarily second $XX.X the Takeda. Roche by the one which a of period. in $XX for Royalty of results. a higher decrease the revenue HYCELA comprised by to partially patient target for Argenx decrease compared impact HYQVIA our in year continuing to rHuPHXX totaled in in Hylenex $XX.X compared of SC million licensing the phase of quarter the prior the due period. for bulk totaled Turning second sales to was in are study. driven of million, RITUXAN compared second in revenue of which prior Europe, quarter first compared was revenue year to higher XX% Roche in XX% sales second by offset Total collaboration a XXXX. to dose selection $X sales to With quarter mainly We're by lower from biosimilars million prior was Product totaled $XX.X and million of for of

was in activity the million period. the to quarter the now detailed operating down were second in Slide XXXX to of the for $X.X product our trial million reduced Research in reflecting slightly administrative in and year in higher year equivalents XXXX, the quarter $XX.X which compared collaboration loss prior million more securities million, million, XX, a million was HALO-XXX. December completion $X.XX to loss compared million of to the million million sales cash which of in of enrollment move quarter compared period. Selling year XXXX. expenses XXXX quarter, X And period. the Turning of second $XX.X Cost on per at million million $X.XX of or reflected $XX.X $XX.X Net the or June $XX.X P&L. a marketable compared XX, impact the second For revenues. share, to $XX.X $XX.X were quarter expenses, and in million in $X.X $XXX.X general compared clinical at of and expenses per share breakdown $XXX.X prior cash, to were the quarter I'll were $XX.X Development from with the total net prior for

Slide like guidance. update to turning to Now our XXXX X, I would

including expect from We $XXX range $XX revenues the to to of million to $XXX to be of total million. $XX continue million, revenue in million royalties

the and are As expected the discussed sales to last product API quarter-to-quarter in quarter fluctuate half to be second of related higher year.

from we to to excess For of by is sales $XXX the the production attainment a prior due million our $XXX to projected maturity for and clear. as events people-related expenses and became data down commercial related to fourth expenses in this similar expect the level $XXX quarter first quarter specifically, expect million operating of based and third API year. of lower $XX $XXX at now in which to in the reported sales million We clinical million, API spending followed date modest our quarter readout data we on guidance million, the

sold expect million, of our down Accordingly, $XXX Cost million. guidance million of $XXX expenses we $XXX now to prior of from $XXX operating excluding million Goods to

quarter our million with sheet million XXXX. operational of royalty to provide continues debt from off expect $XXX million. pay of of $XXX million balance As burn, $XX year-end operating by back cash be from to included And result, in operating million the great expect approximately we to of up million expected prior $XX $XX $XX cash expect our company $XX our flexibility. cash to balance second $XXX down as in to XXXX. Furthermore, we debt to expectation from Not the the now our now $XXX million to range million, repayment we remainder burn million a is to

Helen turn the that, me closing call back with will let provide And comments. to who

Helen Torley

strong you, And already. and Laurie. We've year, accomplished in we events Having the key remainder milestones. multiple of Thank XXXX. made progress the expect multiple milestones in additional

And potential we pillar, and Phase fixed-dose Phase Perjeta new For timing, predict additional of X the can collaborations. this combination initiation results X ENHANZE X Herceptin, for to never include our of while pursue advancement of into [ph] of Phase a announcement candidate we Roche's potential potential are continuing studies. X, additional product course, of

expect close data by hard continued ongoing our for top-line year. patients their of study to and for our talented I the December program pillar, pivotal this And gratitude expressing support X from of in Phase Halozyme advancing our my to our HALO-XXX appreciation we partners. ecology and work by and team want

we're your you that, open please take up the questions. with And call? now ready to Operator, would

Operator

Your you. Cantor a first Thank question [Operator line of Duncan Charles comes Fitzgerald. Instructions] from from

open. Your line is

Charles Duncan

Thanks on for afternoon. nice up afternoon. really questions. your for is this I Helen machine question It speaking fast our espresso taking missed. congrats a like and Good quarter. so quick Laurie, Helen, kicked Because, a Had seems you're you.

a a estimated behind you payments about that? amount again state and thoughts I that over certain think time. period Can and said your of something just you milestone of certain

Helen Torley

the are to have XXXX, slide. for billion at in ENHANZE, estimated that by period substantial XXXX of $XXX know have million, we forget royalty revenue Charles. that from million that of Happy revenue milestones and to have often projection or call revenue which shows $X It's And the on in to, People between a milestones. also $XXX addition potential underestimate royalty a projections coming XXXX. we in the on potential that is you on is the our a we slide projection of potential

of the partners development, getting into partners really those multiple market as it revenues the as the well benefit having generating so in royalty does And as reflect well. and

Charles Duncan

our How may stage insights to the do very Yes, sheet. calculations. collaborations, got I'm earlier more have that's some broad Where going wondering it technology come but see in off I kind account ones? on guess, Should later interest? Obviously, that from? you the the does small collaborations, versus leverage balance of how to see We enough versus stage regard or helpful. future. you use? get large you've do terms the seem of Where's of recent left on With new versus smaller use

Helen Torley

Laurie I'll involved to conversations on comment of turn that to the over Hey, just range Charles, we're in.

Laurie Stelzer

CDXX. are biotech be We to potential pharma example Charles, type how of that beauty Hi, we like the marketed of partners, the for is more a be already continue a you had are versus the larger also only doing? partners instance, and interested Vivo, multiple -- in CMS, with of we stage products earlier partners we've conversations of in And like past. not in great with part products Argenx contracted seeing the our seal with but

wide So well we're recent enhance benefit molecules, we've really starting therapeutic of as in will seen of of Argenx are partners, there and as stages partners, Alexion gamut to as across see as the areas, different with things. of those cycle. a range type that size the And a targets life

Charles Duncan

there but in Is maybe read half? It regard know by is perhaps precise that's we information then your because some the The that any it helpful. second end it what if of into? there timing I I'm think question different? depends science, that's in in been new on was the thought that current to data. earlier But seems Is saying is last Okay, thoughts should that that XXX with I December, that events. you've regarding could it's an on be new? wondering like

Helen Torley

information, Charles, new since our update. last No

is we're patients XXX now months. maturity. waiting the That attained for have events followed and X.X for We all data

do by data sight So have a will December. we good of that line we very have the

Charles Duncan

Okay, Thanks for Good helpful. the reminder. that's quarter.

Operator

Jim Your Fargo. next line Birchenough question of Wells from comes from

is open. line Your

Jim Birchenough

on guess has been on target in Argenx progress. the few target we just progress. had Helen first Hi, that on guys, that our billion much the available I congrats A royalties. questions. seems It before all visibility

above part royalties’ Argenx is royalties? and wondering, of target just I'm billion beyond? Or so is the that And

Helen Torley

just Jim. Yes, let on that, Laurie comment me ask to

Laurie Stelzer

Hi, Jim.

So or around when new move at XXXX, that we billion as into a was conviction just $X for looking products. And we that $X partnerships projection programs increased by our it's had portfolio billion. set the it clinic, of

dollars projecting we're $X XXXX. So still by

Helen Torley

the in I the that was and going includes X the to the of marketed will products about, of XX talking be we're we say year. this it project XX end clinic all by

Jim Birchenough

is, with company. get only Got it? contingency planning you're And an you've the and where but doesn't then XXX, for to it becoming a alluded we work ENHANZE question we know success

a thinking far that how on event crisply the guidance timely or along be and it work well? that so studying in as lines this doesn't what and looks further And only Will start contingency out? company the is will ENHANZE to along pretty XXX the like your clock of

Helen Torley

recognize be that do data. with assumption what as of be as profitability But I based do we will that not we company information what far can we ready talked to about to have company. need that. ready that the And we say to path planning prudent the payment ENHANZE for I and business size is is company. only to be will the the our planning, contingency negative as stress will for event the it XXX in is

Jim Birchenough

XXX. then maybe on just question, And Helen one just final

making Just -- more just less you overall, heading confidence-wise How there's become high you into data? XXX remained you or either or has has pre-clinically would data? or of And say higher? confident anything are into your that that's the going that's anything level if biologically feeling conviction

Helen Torley

conviction is some of when facts X were had which XXXX. in we of December the recorded my Jim, Stage set got the results, unchanged we from

all the at with we a And estimate high passed could based patient If And we effect high treatment we HJ in very had recall, HJ you that at population, population. the of the data good was mature high a define when set. other HJ a looked that the on XX%.

got to was and the answer But do strongly powered we to HALO-XXX much done haven't treatment that We science. believe other that control is the many perhaps we X Stage sufficiently cancer. question of so potential the sight in having address into only pancreas and by you know believe that in study line truth data, better effects is succeeded question. And the the a products sized that which

that our my And unchanged So those us is facts gave conviction. were based those there the on conviction facts.

Jim Birchenough

question. taking thanks Well, the for

Helen Torley

Thanks, Jim.

Operator

you. Thank

Jason line JMP question securities. from next comes from Butler Your of

open. Your line is

Jason Butler

thanks taking Hi, the questions. for

First one just with Tecentriq specifically on you cohort pancreatic for the being Tecentriq, dosing you're schedule? the the that's a additional Can to trial. speak and rationale and the different And cancer gallbladder the then to what the for there looking both trial. gallbladder added on second question the

think year. later I for you both data said this

Just us any of give expected Thanks. that with patient around details can or you numbers maturity update. data

Alison Armour

I'm take I'd conduct study. Hi, And PK unusual Thanks. Alison to the new Phase the XXX the to of carcinoma the Jason. X I And regimen information an Head development. alternative study, during from collegial with had came we of It's in if not that this study the an Armour, R&D. explore like can, additional

X given It's remember Jim collegial different. will X weeks. thing in carcinoma, is platinum, you Now, that is every regimen black given is, the every a which weeks. pancreas slightly A

were the different. So slightly regimens

trial the collegial additional when the study similar be showed fact, data decided it important, the that dozing got then one. make So pancreatic we the to the might to CXX us we from level XXX and in more in

that using science and just we're So here. then doing good information

Helen Torley

is cohort these if first is And be PFS mature data the of rate. the data can would this think pick the data up would initial perhaps a would It And then but be sort be. response it about Jason, populations, The by year. the still we as on a we see. in maturing of at look initial to might enough, even what I what expect end

Jason Butler

a There biosimilars quick impact thoughts Herceptin. pretty you'd a U.S. impacted Great. about Thanks, Europe market looks franchise in how biosimilars just well? was on that the any the to Thanks. quarter, forward and this Helen. as in significant expect then maybe And one going how

Helen Torley

ask me to that. Let Laurie address

Laurie Stelzer

Hi, Jason.

year. for watch to our $XX of closely. continue still this to royalties confident $XX million We're very forecasts million We in this

see impact to We are continuing of biosimilars. the

and You $XX confident Herceptin $XX but we are correct still in on Europe, in to feel million the million.

in that biosimilars to the as year. and of was U.S. did part be the project half there coming biosimilars this that in would plan far we As second U.S. the our

we to anticipated Now into But may are actions we or It have the may aggressive impact entrance half. the in are extent that. second there did the to on market anticipate biosimilars there price our need than look a multiple at greater projections.

we're still within range. So that

Jason Butler

great. taking questions. the Okay, Thanks for

Operator

Your question the Citi. next Instructions] Joel [Operator from of comes line form Beatty

is line Your open.

Joel Beatty

taking the Hi, ENHANZE The Q. sub dynamics the question. is of of market thanks on question IV for formulation the subcutaneous and kind of

an time Some make then products a quite delivery hour maybe the the a shorter. kind by of seems of terms decrease in threshold you the difference identified a and a giving product? bit, of the sometimes bit little Have that big where to to edge partner ENHANZE

Helen Torley

Joel. Thanks,

date. anything example, from to we've IV a the that launched good where Herceptin is was X is XX XX to products minutes in seen usually subQ very we've out, the a As XX. you to difference point and the

sales did Europe subQ. see that in was with of what difference, volume we Now for share the XX%

in all of also the Europe as Roche potential but So was -- proposition a value cost certainly demonstrated because the patients for benefits reduced system. healthcare attractive a very that in for

minutes. value in for right X out quite as go pointing being example, X with as DARZELEX You're patients just to hours, even proposition an to X many the able down appears stronger, to

the think I would is difference DARZELEX need get with I and propositions, the But still on those healthcare ones to product, Roche some difference. are still value for that's attractive based the Certainly, patients the minimal find are products And that what that so we think today. share seem all make so approved a adoption. would far. certainly we five-minute injection. which very professionals to X be

Joel Beatty

or on they're if give That's are mostly substantial product? to great. to just a or any amount a you coming up million development to of provide breakdown milestone payments from of a sense of $XXX a you the those question $XXX able or milestones Maybe million, coming a particular large milestones portion commercial

Helen Torley

that. address will Laurie

Laurie Stelzer

Phase can the I the cycle, of X is as million haven't Joel? move in is moving associated provided say X a are development milestones by be products through the partners to development those it end products programs X. Hi, breakdown with of continue as we year, those I in primarily X to will that milestones Phase development the and What the the $XXX program. majority And million. Well, of $XXX those think our that

Joel Beatty

you. Thank

Operator

time, this There are you. Torley, call the no further over questions CEO, to I President and at turn Helen back Dr.

Helen Torley

for Thank thanks everyone being you for to joining us today. all here. And

continuing look in providing we're to heard, you've the great quarter. we forward to Have you As next Halozyme, with very a make here at an nice progress. evening. update

Operator

conference concludes This today's call.

now disconnect. may You

Halozyme Therapeutics (HALO) 6 Aug 192019 Q2 Earnings call transcript